In a study of 933 non-squamous NSCLC cases, no patients with MET gene exon 14 skipping mutation had mutations in KRAS, EGFR, and ERBB2, or rearrangements in ALK, ROS1, and RET (87). This evidence concerns the gene KRAS and non-small cell lung carcinoma.